Table 3A.

Multivariable model for PFS and OS of significant clinical variables in univariate analysis

PFSOS
HR (95% CI)PHR (95% CI)P
ECOG PS
 ≥2 vs. 0–11.67 (1.1–2.5)0.0042.08 (1.37–3.16)0.001
No. of metastatic sites
 ≥3 vs. <31.7 (1.2–2.3)0.0042.36 (1.62–3.45)<0.001
No. of prior therapies
 ≥3 vs. <31.57 (1.1–2.3)0.0141.73 (1.16–2.6)0.008
Type of ICI therapy
 Combination vs. single-agentNANA0.7 (0.5–1.07)0.096
  • NOTE: Significant values highlighted in bold.